Who is sponsoring NCT01525173?

NCT01525173 is sponsored by Allergan.

What condition does NCT01525173 study?

NCT01525173 studies Glaucoma, Ocular Hypertension.

What drugs are being tested in NCT01525173?

Interventions: 0.1% brimonidine tartrate ophthalmic solution, 0.01% bimatoprost ophthalmic solution, 0.2% hypromellose lubricant eye drops, latanoprost 0.005% ophthalmic solution.

What is the status of NCT01525173?

NCT01525173 is currently COMPLETED.

Last reviewed 2013-10-07 · How we verify

A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension

NCT01525173 Phase 4 COMPLETED Results posted

This study will evaluate the efficacy and safety of either bimatoprost 0.01% ophthalmic solution (Lumigan®) alone or bimatoprost 0.01% ophthalmic solution (Lumigan®) and brimonidine tartrate 0.1% ophthalmic solution (Alphagan® P) in combination in patients previously treated with latanoprost 0.005% ophthalmic solution monotherapy who require additional intraocular pressure (IOP) lowering medication.

Details

Lead sponsor	Allergan
Phase	Phase 4
Status	COMPLETED
Enrolment	137
Start date	2012-01
Completion	2012-10

Conditions

Glaucoma
Ocular Hypertension

Interventions

0.1% brimonidine tartrate ophthalmic solution
0.01% bimatoprost ophthalmic solution
0.2% hypromellose lubricant eye drops
latanoprost 0.005% ophthalmic solution

Primary outcomes

Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) — Baseline, Week 12
IOP is a measurement of the fluid pressure inside the eye. IOP was measured in the study eye, defined as the worse eye at Baseline. The mean diurnal IOP is the average of all the IOP measurements in the study eye taken at 8 AM, 10 AM and 4 PM at Baseline and at Week 12. A negative change from Baseline indicated improvement.

Countries

United States